PEMBROLIZUMAB (Keytruda) prior authorization at UnitedHealthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UnitedHealthcare requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for PEMBROLIZUMAB (Keytruda): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UnitedHealthcare reviews PEMBROLIZUMAB (Keytruda) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. UnitedHealthcare-specific context: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UnitedHealthcare's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- GLP-1 weight-loss exclusion
- Out-of-network reduction citing UCR
- Step therapy on biologics
- Prior auth denied for advanced imaging
- Quantity limits on specialty drugs
PEMBROLIZUMAB (Keytruda)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Off-label indication denial
- Combination therapy denial
- Continuation beyond 2 years
Approved across 30+ cancer types. NCCN compendium often supports off-label uses.
Manufacturer patient-assistance program: Merck Access Program — relevant when a UnitedHealthcare denial sticks and the patient needs bridge access while appealing.
How UnitedHealthcare approaches Immune checkpoint inhibitors PAs
For PEMBROLIZUMAB (KEYTRUDA), check whether the current UnitedHealthcare Immune checkpoint inhibitors policy cites quantity limits on specialty drugs. Pharmacy-benefit review for PEMBROLIZUMAB (KEYTRUDA) at UnitedHealthcare is routed through OptumRx (in-house PBM, parent UnitedHealth Group). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with UnitedHealthcare; if denied, use the filing date and route printed on that denial notice. Off-label oncology appeals at UnitedHealthcare carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. UnitedHealthcare is domiciled in MN, so unresolved appeals escalate to the MN insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.uhcprovider.com) with the same packet plus an applicable, current clinical source supporting PEMBROLIZUMAB (Keytruda)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a UnitedHealthcare denial on DenialHelp.
Contact UnitedHealthcare
- Provider portal: https://www.uhcprovider.com
Frequently asked questions
What documentation does UnitedHealthcare need for PEMBROLIZUMAB (Keytruda) prior auth?
UnitedHealthcare's typical PA packet for PEMBROLIZUMAB (Keytruda): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UnitedHealthcare?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for PEMBROLIZUMAB (Keytruda) at UnitedHealthcare?
Preparation scenarios to check against the current notice and policy include: GLP-1 weight-loss exclusion; Out-of-network reduction citing UCR; Step therapy on biologics. These are not measured frequency claims. For PEMBROLIZUMAB (Keytruda), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does UnitedHealthcare cover off-label use of PEMBROLIZUMAB (KEYTRUDA) supported by NCCN compendium?
UnitedHealthcare may consult the NCCN Drugs & Biologics Compendium for oncology coverage. For off-label PEMBROLIZUMAB (KEYTRUDA), cite the current compendium entry by version and table, name the evidence-block category, and attach the supporting clinical-trial or meta-analysis reference. Verify the member-specific coverage rule and timing before relying on this preparation guide. Pharmacy-benefit handling is routed through OptumRx (in-house PBM, parent UnitedHealth Group). External-review escalation for UnitedHealthcare fully-insured policies sits with the MN insurance department.
How do I prep for a peer-to-peer with UnitedHealthcare on PEMBROLIZUMAB (Keytruda)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the PEMBROLIZUMAB (Keytruda) PA packet
Open ApprovalHelp — generate a PEMBROLIZUMAB (Keytruda) prior-auth packet tailored to UnitedHealthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com